Smruthi Organics Limited

August 06, 2024

Facilities/Instruments	Amount (₹ crore)	Rating[1]	Rating Action
Long Term Bank Facilities	12.00	CARE BBB; Negative	Reaffirmed; Outlook revised from Stable
Long Term / Short Term Bank Facilities	20.00	CARE BBB; Negative / CARE A3+	Reaffirmed; Outlook revised from Stable
Short Term Bank Facilities	13.00	CARE A3+	Reaffirmed

Details of instruments/facilities in Annexure-1.

Rationale and key rating drivers

The reaffirmation of the ratings to the bank facilities of Smruthi Organics Limited (SOL) continues to derive comfort from extensive experience of promoters in the pharmaceutical industry, accredited manufacturing facilities, and comfortable financial risk profile. These rating strengths, however, remain tempered by moderate scale of operations, decline in profitability, product and customer concentration risk, competitive nature of business, exposure to volatility in raw material prices, regulatory and foreign exchange fluctuation risk.

Rating sensitivities: Factors likely to lead to rating actions

Positive factors

- Increase in TOI to more than ₹300 crore along with operation margin of 18% and above on sustained basis
- Ability of the company to reduce the therapeutic concentration risk with no segment contributing more than 30% along with diversifying its customer base
- Ability of the company to diversify geographically with significant level of revenues from regulated markets

Negative factors

- Ability of the company to diversify geographically with significant level of revenues from regulated markets
- TOI falling below ₹100 crore and PBILDT margin falling below 10% on a sustained basis

Analytical approach: Standalone

Outlook: Negative

The revision in the outlook from 'Stable' to 'Negative' reflects CARE's expectation of moderation in SOL's performance owing to continued pricing pressure for its key products. The outlook may be revised to 'Stable' if the company is able to achieve higher than envisaged sales growth in the medium term along with improvement in its profitability.

Detailed description of the key rating drivers:

Key strengths

Comfortable Financial risk Profile

As on March 31, 2024, the overall gearing of the company stood comfortable at 0.17x (PY: 0.08x). The debt coverage indicators also remained satisfactory marked by total debt/ GCA which stood at 1.27x for FY24 (refers to April 1 to March 31) as against 0.75x for FY23. Interest coverage remained healthy at 8.53x during FY24 (11.92x during FY23).

Experienced promoters in the bulk drug manufacturing Industry

SOL is managed/promoted by Mr. Purushotham Eaga and Mr. Swapnil Eaga, having more than 30 years and 15 years respectively in pharmaceutical industry. SOL's operating track record is of more than three decades in the pharmaceutical business with presence in the area of manufacturing of bulk drugs and APIs.

Accredited manufacturing units

The company has two manufacturing units located at Solapur in Maharashtra. The facilities are spread over an area of 22 acres with total annual capacity of around 5,800 MT, thus capable of handling large volumes. The plant is Good Manufacturing Practice (GMP) certified. The company's research and development department is recognized by the Directorate of Scientific and Industrial Research (DSIR), Government of India.

[1]Complete definition of the ratings assigned are available at www.careedge.in and other CARE Ratings Ltd.'s publications

Key weaknesses

Moderate scale of operations
SOL's TOI has remained moderate in range of Rs.125 crore to Rs.140 crore during FY20- FY24. During FY24, the revenue of the company declined and remained at Rs. 127.72 crore as against Rs.141.06 crore in FY23. During Q1FY25 (refers to period April 1 to June 30), TOI further declined by ~22% to Rs.27.27 crore from Rs.34.91 crore in Q1FY24. Continued pressure on selling prices for SOL's key products in domestic and international markets led to the decline. In the near term, prices are expected to remain low, which could affect SOL's sales growth.

Moderate profitability
PBILDT margin of the company improved from 6.95% in FY23 to 9.42% in FY24, mainly benefitting from lower raw material prices. PAT margin of the company remained in line with previous year at 2.81% in FY24 as against 2.93% in FY22.
However, during Q1FY25, lower sales significantly impacted SOL's profitability. PBILDT margin deteriorated to 1.61% as compared to 13.26% during Q1FY24. SOL reported net losses of Rs.0.92 crore during Q1FY25 as against PAT of Rs.2.29 crore in Q1FY24. SOL's ability to derive envisaged benefits from ongoing capex related to debottlenecking and cost optimization and improve its profitability would remain a key rating monitorable.

Susceptibility of operating margins to volatile raw material prices and foreign exchange rate
The key raw materials are procured from imports as well as domestic market, prices of which are volatile in nature. Since, raw material is the major cost driver for the company, any upward movement in raw material prices, with limited increase in prices of finished products in an intensely competitive industry may result in adverse performance of the company. Further, SOL imports approximately 42% of its raw material from China and exports its products to several countries like Pakistan, Thailand, Argentina etc with no long- term contracts with its customers. In the absence of a hedging mechanism, although being a net exporter, the company is exposed to foreign currency fluctuation risk owing to timing differences

Product and customer concentration Risk
SOL is primarily an API manufacturer, with APIs representing more than 80% of revenue contribution and the remaining is accounted by intermediates. The product portfolio of the company is skewed as top 5 products derived close to 95% of the revenue in 9MFY24 (refers to period April 1 to December 31) as against 95% in FY23. The share of top two products stood at over 55% of the revenue in FY23 and 9MFY24 each reflecting high dependence on sales from top two products i.e. Metformin and Telmisartan. Furthermore, the customer concentration of the company continues to remain high with top 10 customer contributed over 70% of total sales in FY23 and 9MFY24.

Exposure to regulatory risk
The pharmaceutical industry is highly regulated and requires various approvals, licenses, registrations, and permissions for business activities. Each authority has its own requirement, and they could delay or refuse to grant approval, even when a product has already been approved in another country. The approval process for a new product registration is complex, lengthy, and expensive. Any delay or failure in getting approval for a new product launch could adversely affect the business prospects of the company. This apart, the ability of the company to continue to observe the regulatory and CGMP standards without receiving any adverse observations from regulatory authorities remains critical from a business and credit risk perspective. Furthermore, the company has substantial level of imports from China and exports to Pakistan, any geopolitical issues with such countries could materially impact the operations of the company.

Liquidity: Adequate
The company has adequate liquidity position characterized by expected net cash accruals as against scheduled debt repayment obligations. With a gearing of 0.17x as of March 31, 2024, the company has sufficient gearing headroom to raise additional debt. Further, its unutilized bank lines are adequate to meet its incremental working capital needs over the next one year as bank limits are utilized to the extent of 40% in the last 12 months ended July 31, 2024.

Applicable criteria
Definition of Default
Liquidity Analysis of Non-financial sector entities
Rating Outlook and Rating Watch
Manufacturing Companies
Pharmaceuticals
Financial Ratios – Nonfinancial Sector
Short Term Instruments

About the company and industry

Industry classification

Macro-Economic Indicator	Sector	Industry	Basic Industry
Healthcare	Healthcare	Pharmaceuticals & Biotechnology	Pharmaceuticals

SOL was established in 1989 by Mr. Purushotham Eaga (Managing Director) and is headquartered at Solapur, Maharashtra. Mr. Purushotham Eaga along with his son Mr. Swapnil Eaga manages the overall operations of the company. The company is engaged in the business of manufacturing and marketing active pharmaceutical ingredients (APIs) and intermediates. The product portfolio of the company consists of various APIs and intermediates including Metformin, Diloxanide Furoate, Norfloxacin, Telmisartan, Amlodipine, Potassium Losartan amongst others.

Brief Financials (₹ crore)	March 31, 2023 (A)	March 31, 2024 (A)	Q1FY25 (Abridged)
Total operating income	141.06	127.72	27.27
PBILDT	9.80	12.03	0.44
PAT	4.13	3.59	(0.92)
Overall gearing (times)	0.08	0.17	NA
Interest coverage (times)	11.92	8.53	1.07

A: Audited; NA: Not available Note: 'the above results are latest financial results available'

Status of non-cooperation with previous CRA: Not applicable

Any other information: Not applicable

Rating history for last three years: Please refer Annexure-2

Covenants of rated instrument / facility: Detailed explanation of covenants of the rated instruments/facilities is given in Annexure-3

Complexity level of various instruments rated: Annexure-4

Lender details: Annexure-5

Annexure-1: Details of instruments/facilities

Name of the Instrument	ISIN	Date of Issuance (DD-MM-YYYY)	Coupon Rate (%)	Maturity Date (DD-MM-YYYY)	Size of the Issue (₹ crore)	Rating Assigned along with Rating Outlook
Fund-based - LT-Term Loan		-	-	31/10/2030	12.00	CARE BBB; Negative
Fund-based - LT/ ST-CC/Packing Credit		-	-	-	20.00	CARE BBB; Negative / CARE A3+
Non-fund-based - ST-BG/LC		-	-	-	13.00	CARE A3+

Annexure-2: Rating history for the last three years

Sr. No.	Name of the Instrument/Bank Facilities	Current Ratings			Rating History			
		Type	Amount Outstanding (₹ crore)	Rating	Date(s) and Rating(s) assigned in 2024-2025	Date(s) and Rating(s) assigned in 2023-2024	Date(s) and Rating(s) assigned in 2022-2023	Date(s) and Rating(s) assigned in 2021-2022
1	Fund-based - LT/ ST-CC/Packing Credit	LT/ST	20.00	CARE BBB; Negative / CARE A3+	-	1)CARE BBB; Stable / CARE A3+ (13-Feb-24)	1)CARE BBB; Stable (13-Mar-23)	1)CARE BBB; Stable (05-Jan-22) 2)CARE BB+; Stable; ISSUER NOT COOPERATING* (13-Aug-21)
2	Non-fund-based - ST-BG/LC	ST	13.00	CARE A3+	-	1)CARE A3+ (13-Feb-24)	1)CARE A3+ (13-Mar-23)	1)CARE A3+ (05-Jan-22) 2)CARE A4+; ISSUER NOT COOPERATING* (13-Aug-21)
3	Fund-based - LT-Term Loan	LT	12.00	CARE BBB; Negative	-	1)CARE BBB; Stable (13-Feb-24)	-	-

*Issuer did not cooperate; based on best available information.
LT: Long term; ST: Short term; LT/ST: Long term/Short term

Annexure-3: Detailed explanation of covenants of the rated instruments/facilities: Not applicable

Annexure-4: Complexity level of the various instruments rated

Sr. No.	Name of the Instrument	Complexity Level
1	Fund-based - LT-Term Loan	Simple
2	Fund-based - LT/ ST-CC/Packing Credit	Simple
3	Non-fund-based - ST-BG/LC	Simple

Annexure-5: Lender details

To view the lender wise details of bank facilities please click here

Note on the complexity levels of the rated instruments: CARE Ratings has classified instruments rated by it on the basis of complexity. Investors/market intermediaries/regulators or others are welcome to write to care@careedge.in for any clarifications.

Contact us

Media Contact	**Analytical Contacts**
Mradul Mishra Director **CARE Ratings Limited** Phone: +91-22-6754 3596 E-mail: mradul.mishra@careedge.in	Akhil Goyal Director **CARE Ratings Limited** Phone: +91-22-6754 3590 E-mail: akhil.goyal@careedge.in
Relationship Contact Ankur Sachdeva Senior Director **CARE Ratings Limited** Phone: 91 22 6754 3444 E-mail: Ankur.sachdeva@careedge.in	Ashish Kashalkar Assistant Director **CARE Ratings Limited** Phone: +91-20-4000-9069 E-mail: Ashish.Kashalkar@careedge.in Akhil Thakrar Analyst **CARE Ratings Limited** E-mail: akhil.thakrar@careedge.in

About us:

Established in 1993, CARE Ratings is one of the leading credit rating agencies in India. Registered under the Securities and Exchange Board of India, it has been acknowledged as an External Credit Assessment Institution by the RBI. With an equitable position in the Indian capital market, CARE Ratings provides a wide array of credit rating services that help corporates raise capital and enable investors to make informed decisions. With an established track record of rating companies over almost three decades, CARE Ratings follows a robust and transparent rating process that leverages its domain and analytical expertise, backed by the methodologies congruent with the international best practices. CARE Ratings has played a pivotal role in developing bank debt and capital market instruments, including commercial papers, corporate bonds and debentures, and structured credit.

For the detailed Rationale Report and subscription information, please visit www.careedge.in